Clinical trials: Neuron Disease, Motor
Muscular Atrophy, Spinal
A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients
The objectives of this trial are: to establish a safety profile for use of Hydroxyurea in children with Type I Spinal Muscular Atrophy; to identify reliable outcome measures for HU treatment in Type I SMA; and to detect the…
- Trial name
- NCT00568698
- Testing
- Hydroxyurea
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Stanford University
Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development
Spinal muscular atrophy (SMA) is the leading genetic cause of death of infants. Strong preclinical evidence suggests that effective therapy must be delivered as early as possible to prevent progression of the disease.
- Trial name
- NCT01736553
- Where
- 15 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Amyotrophic Lateral Sclerosis
A Study of Ranolazine in ALS
The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.
- Trial name
- NCT06527222
- Testing
- Ranolazine
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- Swathy Chandrashekhar, MBBS
Amyotrophic Lateral Sclerosis
Multimodal Brain Imaging Study
To explain the key brain network nodes and their brain mechanisms of ALS language cognitive impairment and decline, reveal the neural mechanism of the association between ALS language cognitive impairment and motor executive…
- Trial name
- NCT04960540
- Testing
- MRI,
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University Third Hospital
ALS (Amyotrophic Lateral Sclerosis), Postpoliomyelitis Syndrome
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
Motor neuron disease (MND) or ALS is a nervous system disease. ALS leads to a loss of movement ability that eventually leads to death. At the moment, there is no known treatment for ALS.
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), Postpoliomyelitis Syndrome, Spinal Muscular Atrophy
- Trial name
- MotorMarker (NCT05663008)
- Testing
- 128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)
- Where
- Ireland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Dublin, Trinity College
Muscular Atrophy, Spinal
A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies
The aim of this study was to assess real-world dosing patterns, long-term healthcare costs, and characteristics of SMA patients who received treatment with DMTs. DMTs included onasemnogene abeparvovec, nusinersen, and risdiplam.
- Trial name
- NCT07378943
- Where
- United States
- Volunteers
- 4,114 people
- Sponsor
- Novartis Pharmaceuticals
Spinal Muscular Atrophy (SMA)
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor…
- Trial name
- NCT04174157
- Testing
- Prospective observational registry, Zolgensma
- Where
- 99 sites in United States, Greece and 9 more
- Volunteers
- 700 people
- Sponsor
- Novartis Pharmaceuticals
Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis)
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
- Conditions
- Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis), Motor Neuron Disease, ALS - Amyotrophic Lateral Sclerosis
- Trial name
- NCT07543367
- Testing
- Stentrode
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Synchron, Inc.
Amyotrophic Lateral Sclerosis, Sporadic, Amyotrophic Lateral Sclerosis
ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach
RNALS is a multicentre, transversal, diagnostic and non-interventional study carried out in ALS reference centers; in order to identify a diagnostic signature for Amyotrophic Lateral Sclerosis by analyzing of coding and…
- Trial name
- RNALS (NCT05928416)
- Testing
- Saliva sample
- Where
- 19 sites in France
- Volunteers
- 653 people, healthy volunteers welcome
- Sponsor
- ZIWIG
Amyotrophic Lateral Sclerosis (ALS)
A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS
The purpose of this trial is to evaluate safety and efficacy of intrathecal delivery of VGN-R13 as a treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT06849609
- Testing
- VGN-R13
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Hong Chen
Muscular Atrophy, Spinal
A Real-World Study of Clinical Use of Available Treatments for Pediatric Patients With Spinal Muscular Atrophy
The aim of this study was to evaluate real-world treatment patterns and clinical outcomes in pediatric SMA patients in the Czech and Slovak Republics, using data from the Registry of muscular Dystrophy (REaDY).
- Trial name
- NCT07474311
- Where
- Czechia
- Volunteers
- 213 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
Tongue Strength in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease with a poor prognosis that occurs in adults 64 years on average. Its prevalence is 4 to 6/100 000 inhabitants.
- Trial name
- NCT02665663
- Testing
- medical device
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Child With Cancer, Muscular Atrophy, Spinal
A BHI to Increase Hope Level and Stress Level of Parents With a CMC
Being a parent of a child with medical complexity (CMC) poses an enormous stress because these CMC have a multisystem disease, a severe neurologic condition or cancer which may result in premature death.
- Conditions
- Child With Cancer, Muscular Atrophy, Spinal, Child With Cerebral Palsy, Endocrine System Diseases
- Trial name
- NCT05269693
- Testing
- Brief Hope Intervention
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Hong Kong Polytechnic University
Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure
A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)
Amyotrophic lateral sclerosis (ALS) is a disease that causes weakness of the muscles of the body. The disease can eventually lead to severe breathing problems, which is the most common cause of death from ALS.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure, Neuromuscular Disease Patients, Neuromuscular Disease
- Trial name
- EVENT ALS (NCT07071935)
- Testing
- Non-invasive ventilation
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Pennsylvania
Amyotrophic Lateral Sclerosis, ALS
Phase II Study Using Thalidomide for the Treatment of ALS
The use of Thalidomide in patients with ALS who have disease progression.
- Trial name
- NCT00140452
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Motor Neurone Disease
Assessment of the Effects of Sheffield Support Snood in MND Patients
The aim of this study is to evaluate the effects on MND patients of a new collar specifically designed for people affected by neck weakness: the Sheffield Support Snood.
- Trial name
- NCT02464852
- Testing
- Head movements, Activities of daily living (drinking, washing hand and eating), Sheffield Support Snood
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer…
- Trial name
- TulmiSTAR-02 (NCT07190300)
- Testing
- Tulmimetostat, Darolutamide, Abiraterone
- Where
- 31 sites in United States, Australia and 12 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis, ALS
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Phase 1, open-label study of BHV-0223 in ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease
- Trial name
- NCT03520517
- Testing
- BHV-0223
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis
Frequency of SOD1 and C9orf72 Gene Mutations in French ALS
The purpose of the study is to determine the frequency of mutations in the C9orf72 and SOD1 genes in the incident population of ALS patients followed in the FILSLAN centres
- Trial name
- GENIALS (NCT04819555)
- Testing
- Blood
- Where
- 20 sites in France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Tours
Spinal Muscular Atrophy
Longitudinal Data Collection in Pediatric and Adult Patients With Spinal Muscular Atrophy in Latin America
The natural history of SMA patients has changed, due to the improvements in treatment and technological advances. The systematic collection of data from routine clinical practice in multiple Latin American countries, harmonized…
- Trial name
- RegistrAME (NCT05475691)
- Where
- 18 sites in Argentina, Brazil and 4 more
- Volunteers
- 361 people
- Sponsor
- Hospital Israelita Albert Einstein
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.